These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 20157701

  • 1. Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.
    Gudbjornsson B, Thorsteinsson SB, Sigvaldason H, Einarsdottir R, Johannsson M, Zoega H, Halldorsson M, Thorgeirsson G.
    Eur J Clin Pharmacol; 2010 Jun; 66(6):619-25. PubMed ID: 20157701
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study.
    Huang WF, Hsiao FY, Tsai YW, Wen YW, Shih YT.
    Drug Saf; 2006 Jun; 29(3):261-72. PubMed ID: 16524325
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
    Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.
    Lee YH, Ji JD, Song GG.
    Rheumatol Int; 2007 Mar; 27(5):477-82. PubMed ID: 17051359
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

  • 8. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

  • 9. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Jul; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 10. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.
    Ann Intern Med; 2005 Feb 01; 142(3):157-64. PubMed ID: 15684203
    [Abstract] [Full Text] [Related]

  • 11. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 01; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 12. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP, Deray G, Héloire F.
    Presse Med; 2006 Sep 01; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [Abstract] [Full Text] [Related]

  • 13. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
    Spalding WM, Reeves MJ, Whelton A.
    Am J Ther; 2007 Sep 01; 14(1):3-12. PubMed ID: 17303969
    [Abstract] [Full Text] [Related]

  • 14. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.
    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.
    Drug Saf; 2005 Sep 01; 28(9):803-16. PubMed ID: 16119973
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Cunnington M, Webb D, Qizilbash N, Blum D, Mander A, Funk MJ, Weil J.
    Pharmacoepidemiol Drug Saf; 2008 Jun 01; 17(6):601-8. PubMed ID: 18383442
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.